Publications
186
Citations
1,397
Est. group size
~27
Recurring co-author estimate
Active years
34
Publishing since 1993
Typically publishes in teams of ~14 · 12% small-team papers (≤3 authors) · across 14 venues
- Tucatinib–trastuzumab–capecitabine for treatment of leptomeningeal metastasis in women with HER2+ breast cancer: TBCRC049 phase 2 study results
Nature Cancer · 2026
- Phase 1/2 study of H3B-6545 in women with locally advanced/metastatic estrogen receptor-positive, HER2-negative breast cancer
Breast Cancer Research · 2025
- Phase 1/2 study of H3B-6545 in women with locally advanced/metastatic estrogen receptor-positive, HER2-negative breast cancer
UNC Libraries · 2025
- Tucatinib-trastuzumab-capecitabine for treatment of leptomeningeal metastasis in HER2+ breast cancer: TBCRC049 phase 2 study results.
Journal of Clinical Oncology · 2024
- H3B-6545 in women with locally advanced/metastatic estrogen receptor-positive (ER+), HER2 negative (–) breast cancer (BC).
Journal of Clinical Oncology · 2024
- Abstract PO3-18-12: Results from a first-in-human study of DAN-222, a novel high-capacity drug conjugate in metastatic breast cancer as monotherapy and in combination with a PARPi [NCT05261269]
Cancer Research · 2024
- Molecular profiling of serial liquid biopsy specimens utilizing cell free DNA (cfDNA) and circulating tumor cells (CTCs) in TBCRC041: A phase II study of alisertib in endocrine resistant metastatic breast cancer (MBC).
Journal of Clinical Oncology · 2024
- Evaluation of Alisertib Alone or Combined With Fulvestrant in Patients With Endocrine-Resistant Advanced Breast Cancer
JAMA Oncology · 2023
- Intrathecal trastuzumab versus alternate routes of delivery for HER2-targeted therapies in patients with HER2+ breast cancer leptomeningeal metastases
The Breast · 2023
- Abstract OT2-11-01: A phase 1 study of the novel immunotoxin MT-5111 in patients with HER2+ tumors: interim results
Cancer Research · 2023
- Supplementary Table S1 from Palbociclib for the Treatment of Estrogen Receptor–Positive, HER2-Negative Metastatic Breast Cancer
2023
- Data from Palbociclib for the Treatment of Estrogen Receptor–Positive, HER2-Negative Metastatic Breast Cancer
2023
- Data from Palbociclib for the Treatment of Estrogen Receptor–Positive, HER2-Negative Metastatic Breast Cancer
2023
- Supplementary Table S1 from Palbociclib for the Treatment of Estrogen Receptor–Positive, HER2-Negative Metastatic Breast Cancer
2023
- A systematic review and meta-analysis of intrathecal versus alternate routes of delivery for HER2-targeted therapies in patients with HER2+ breast cancer leptomeningeal metastases.
Journal of Clinical Oncology · 2023
- Cancer Research×25
- Journal of Clinical Oncology×18
- Neuro-Oncology Advances×7
- Neuro-Oncology×4
- Breast Cancer Research and Treatment×3
- Habib Serhan
Medicine · University of Michigan
- Jinju Li
Medicine · University of Michigan
- Athena Apfel
Medicine · University of Michigan
- Alex Hopkins
Medicine · University of Michigan
- Nathan Merrill
Medicine · University of Michigan
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 25, 2026.
Claim or correct this profile